Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes
August 23, 2018 at 11:47 pm EDT
Share
Genomma Lab Internacional, S.A.B. de C.V. announced that Jorge Luis Brake Valderrama has been named as Chief Executive Officer, in line with the company's ongoing long-term strategic and succession planning, effective September 10, 2018. Mr. Juda will remain active at Genomma in an advisory role to Mr. Brake to ensure a smooth transition. Mr. Brake joins Genomma with more than 25 years of related industry experience with The Procter and Gamble Company as CEO of P&G's Latin America division.
His most recent role as Senior Vice President at Laureate Education Inc. Effective August 22, 2018, Mr. Marco Sparvieri, currently Executive Vice President of Sales, has expanded his responsibilities to become Executive Vice President of Operations. Mr. Santiago Velez, who is currently Vice President of Manufacturing, will also be in charge of R&D, becoming Executive Vice President of Manufacturing and R&D.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.